

# Tonga

Population 2016

<1 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	<0.01 (<0.01–<0.01)	0.71 (0.43–1)
Mortality (HIV+TB only)	0 (0–0)	0 (0–0)
Incidence (includes HIV+TB)	<0.01 (<0.01–0.011)	8.6 (7.3–9.9)
Incidence (HIV+TB only)	0 (0–0)	0 (0–0)
Incidence (MDR/RR-TB)**	<0.01 (0–<0.01)	0.48 (0.25–0.7)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	<0.01 (<0.01–<0.01)	<0.01 (<0.01–<0.01)	<0.01 (<0.01–<0.01)
Males	<0.01 (<0.01–<0.01)	<0.01 (<0.01–<0.01)	<0.01 (<0.01–<0.01)
Total	<0.01 (<0.01–<0.01)	<0.01 (<0.01–<0.01)	<0.01 (<0.01–0.011)

TB case notifications, 2016	
Total cases notified	8
Total new and relapse	8
- % tested with rapid diagnostics at time of diagnosis	0%
- % with known HIV status	100%
- % pulmonary	75%
- % bacteriologically confirmed among pulmonary	83%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.08 (0.05–0.12)

TB/HIV care in new and relapse TB patients, 2016		
	Number	(%)
Patients with known HIV-status who are HIV-positive	0	0%
- on antiretroviral therapy	0	

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			0 (0–0)
Estimated % of TB cases with MDR/RR-TB	5.5% (3–8)	26% (23–30)	
% notified tested for rifampicin resistance	0%		0
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 0, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 0, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2015	93%	14
Previously treated cases, excluding relapse, registered in 2015		0
HIV-positive TB cases registered in 2015		0
MDR/RR-TB cases started on second-line treatment in 2014		0
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017	
National TB budget (US\$ millions)	<1

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB